Transform treatment for immune-mediated diseases, empower people to reimagine their lives.
About Alumis
We are advancing a late-stage portfolio of next-generation targeted therapies to optimize patient outcomes across a wide range of immune-mediated diseases.
PIPELINE
Our precision approach builds on integrated scientific insights – powered by our proprietary data analytics platform – to drive smarter therapeutic development.
science
We foster a culture where teams elevate, challenge, and nurture each other, living our values while driving our mission forward.
careers
August 10, 2026 Envudeucitinib Long-term Data Positioned to Set a New Standard for Plaque Psoriasis Treatment, Delivering Highest Reported PASI 100 Skin Clearance Among Oral Therapies
May 14, 2026 Alumis Reports First Quarter 2026 Financial Results and Highlights Recent Achievements
March 28, 2026 Alumis’ Envudeucitinib Delivers Early and Robust Improvements in Skin Clearance, Quality of Life and Psoriasis Symptoms in Two Phase 3 Trials, Underscoring Its Potential as a Leading Oral Therapy for Plaque Psoriasis
More News
